TY - JOUR T1 - Challenges in Tracking the Risk of COVID-19 in Bangladesh: Evaluation of A Novel Method JF - medRxiv DO - 10.1101/2021.08.03.21261567 SP - 2021.08.03.21261567 AU - Md. Enamul Hoque AU - Md. Shariful Islam AU - Arnab Sen Sharma AU - Rashedul Islam AU - Mohammad Ruhul Amin Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/05/2021.08.03.21261567.abstract N2 - Identifying actual risk zones in a country where the overall test positive rate (TPR) is higher than 5% is crucial to contain the pandemic. However, TPR-based risk zoning methods are debatable since they do not consider the rate of infection in an area and thus, it has been observed to overestimate the risk. Similarly, the rate of infection in an area has been noticed to underestimate the risk of COVID-19 spreading for the zones with higher TPR. In this article, we discuss the shortcomings of currently available risk zoning methods that are followed in the lower-middle-income countries (LMIC), especially in Bangladesh. We then propose to determine a risk zone by combining the rate of infection with TPR and effective reproduction number, Rt in a distinct manner from existing methods. We evaluate the efficacy of the proposed method with respect to the mass-movement events and show its application to track the evolution of COVID-19 pandemic by identifying the risk zones over time. Demo website for the visualization of the analysis can be found at: http://erdos.dsm.fordham.edu:3000CCS CONCEPTSApplied computing → Health informatics.ACM Reference Format Md. Enamul Hoque, Md. Shariful Islam, Arnab Sen Sharma, Rashedul Islam, and Mohammad Ruhul Amin. 2021. Challenges in Tracking the Risk of COVID-19 in Bangladesh: Evaluation of A Novel Method. In Proceedings of August 15 (KDD Workshop on Data-driven Humanitarian Mapping, 27th ACM SIGKDD Conference). ACM, New York, NY, USA, 7 pages.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe collected the number of COVID-19 RT-PCR tests, positive cases, and death data of each district in Bangladesh on a daily basis from the Institute of Epidemiology Disease Control and Research (IEDCR) website for the analysis presented in this paper. In addition to this, we collected COVID-19 status reports for each country from the Our World In Data (OWID) website. Also, SARS-CoV-2 sequences submitted from Bangladesh till May 2021 were obtained from GISAID (PMCID: PMC5388101). ER -